openPR Logo
Press release

Hepatocellular Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

05-15-2018 05:02 PM CET | Health & Medicine

Press release from: Precision Business Insights

Hepatocellular Carcinoma Disease Pipeline Drugs

Hepatocellular Carcinoma Disease Pipeline Drugs

Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Overview:

Hepatocellular Carcinoma is the most common primary tumour of liver. It is caused to the people who are having underlying liver diseases such as hepatitis B or C virus, Cirrhosis and non – alcoholic fatty liver disease. HCC does not cause any symptoms in the early stages of diseases. Some of the symptoms of HCC includes loss of appetite, weight loss, nausea and vomiting, upper abdominal pain and swelling, jaundice, white and chalky stools etc.
HCC can be prevented by taking hepatitis vaccination. HCC can be diagnosed by blood tests, CT scan, MRI, Liver tissue biopsy. General treatment of HCC includes liver transplantation, surgery, Radiation Therapy, Transcatheter Arterial Chemoembolization, Brachytherapy, Targeted Drug Therapy, Palliative care

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
By Trial Phase, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Eisai Inc.
• Astellas Pharma Inc
• Pfizer
• Astra Zeneca
• Hoffmann-La Roche
• GlaxoSmithKline
• Oncozyme Pharma Inc.
• Novartis Pharmaceuticals
• Eli Lily & Co
• Bristol-Myers Squibb
By Drugs, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Regorafenib
• SorafenibTosylate
• Lenvatinib
• Sorafenib
• Pentamidine
• Brivanib
• Capecitabine
• Ramucirumab
• Others
By Route of Administration, Hepatocellular Carcinoma pipeline drugs are segmented as:
• Oral
• Parenteral

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

Space Analysis:
• In September 2017, Onxeo S.A released the top line results of phase III Relive trial of Livatag (Doxorubicin Transdrug) in adult patients with unresectable hepatocellular carcinoma (HCC). Results determined that the overall safety and tolerability of Livatag in Relive was favourable with fully manageable toxicity profile in both groups of Livatag20mg/m² and 30mg/m²) and also in patients who has undergone longest treatment period. Thw overall tolerability was comparable to the one observed in comparative group.
• In July 2017, Eisai Inc submitted a supplemental New Drug Application to U.S. FDA for first line use of its lenvatinib (Lenvima) a multiple receptor tyrosine kinaseinhibitor(including fibroblast growth factor receptors [FGFR] 1 – 4), in patients with hepatocellular carcinoma (HCC).

Report Description:
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Hepatocellular Carcinoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Hepatocellular Carcinoma disease pipeline drugs development. This report studies the dynamics of the Hepatocellular Carcinoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Hepatocellular Carcinoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/hepatocellular-carcinoma-disease-pipeline-drugs-assessment/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatocellular Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here

News-ID: 1050646 • Views:

More Releases from Precision Business Insights

Biochar Market Growth Is Attributed To The Increased Production Of Biochar Through Pyrolysis Technology
Biochar Market Growth Is Attributed To The Increased Production Of Biochar Throu …
According to Precision Business Insights (PBI), the latest report biochar market was valued at USD 243.8 million in 2022, growing at a 12.6% CAGR during the forecast period 2023 to 2029. The rising demand for organic and eco-friendly products drives the biochar market. Utilizing biochar corresponds with organic farming methods, improving market prospects. Furthermore, biochar is a potential material for water treatment and remediation because of its capacity to absorb
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Membrane Separation Technology
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Me …
According to Precision Business Insights (PBI), latest report vapor recovery units market was valued at USD 923.7 million in 2022 and is poised to grow at a CAGR of 4.2% during the forecast period 2023 to 2029. The adoption of stringent environmental regulations by governments and international bodies to reduce air pollution and greenhouse gas emissions in various countries drives the demand for the vapor recovery unit's market. Furthermore, the
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
According to Precision Business Insights (PBI), latest report pyrite market is growing at 4.9% CAGR during the forecast period 2023 to 2029. The increased application of pyrite in the manufacturing of sulfuric acid drives the pyrite market. The increase of prices of gold has led to increased demand for imitation jewelry which is anticipated to propel the pyrite market growth. Furthermore, the demand for sulphuric acid in a variety of
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Generation
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Gen …
According to Precision Business Insights (PBI), the latest report industrial boilers market size was valued at USD 15,261.8 million in 2022 and is poised to grow at a 3.1% CAGR during the forecast period 2023 to 2029. The adoption of stringent environmental regulations to maintain emission standards and carbon reduction in several countries drives the industrial boilers market. Furthermore, the advancement in boiler technology, such as better combustion systems, greater

All 5 Releases


More Releases for Hepatocellular

Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy
Hepatocellular Carcinoma HCC Treatment Market: Global Forecast over 2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated
Hepatocellular Carcinoma Global Clinical Trials Review H2 2017
ReportsWeb.com published “Hepatocellular Carcinoma Global Clinical Trials Review H2 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: Publisher's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular
Trends in the Hepatocellular Carcinoma HCC Treatment Market 2016-2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated
Hepatocellular Carcinoma Market 2024: Opportunity Analysis and Forecasts
"The Latest Research Report OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Hepatocellular Carcinoma Market Liver cancer is the second leading cause of cancer related death in the world in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) is the most dominant form of liver
Hepatocellular Carcinoma HCC Treatment Market Growth and Forecast 2016-2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated